Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Annals of the Rheumatic Diseases Année : 2021

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

Résumé

Objectives: To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors of low disease activity (LDA)/remission. Methods: PsABio is a prospective, observational cohort study of patients with psoriatic arthritis (PsA) at 92 sites in eight European countries, who received first-line to third-line ustekinumab or a TNFi. Comparative achievement at 6 months of clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) LDA/remission, and minimal disease activity (MDA)/very LDA using propensity score (PS)-adjusted multivariate logistic regression was assessed. Results: In the final analysis set of 868 participants with 6-month follow-up data (ustekinumab, n=426; TNFi, n=442), with long-standing disease and a high mean cDAPSA score (31.0 vs 29.8, respectively), proportions of patients in ustekinumab/TNFi treatment groups achieving cDAPSA LDA at 6 months were 45.7%/50.7%. cDAPSA remission was achieved in 14.9%/19.2%, and MDA in 26.4%/30.8% of patients. PS-adjusted odds ratios (OR; 95% confidence interval (CI)) of reaching cDAPSA LDA and MDA were 0.73 (0.46 to 1.15) and 0.87 (0.61 to 1.25) with ustekinumab versus TNFi, indicating no significant difference. High baseline body mass index or high cDAPSA were associated with a lower chance (OR (95% CI)) of reaching cDAPSA LDA with TNFi (0.94 (0.89 to 0.99) and 0.64 (0.52 to 0.79), respectively). Predictive factors were similar to previously published evidence, with cDAPSA and 12-item Psoriatic Arthritis Impact of Disease scores and chronic widespread pain at baseline appearing as new risk factors for unfavourable outcome. Safety data were similar between groups. Conclusion: Treatment targets were reached similarly after 6 months of treatment with ustekinumab and TNFi.
Fichier principal
Vignette du fichier
annrheumdis-2021-220263.full.pdf (904.54 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03272138 , version 1 (28-06-2021)

Identifiants

Citer

Josef S Smolen, Stefan Siebert, Tatiana V Korotaeva, Carlo Selmi, Paul Bergmans, et al.. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Annals of the Rheumatic Diseases, 2021, pp.annrheumdis-2021-220263. ⟨10.1136/annrheumdis-2021-220263⟩. ⟨hal-03272138⟩
38 Consultations
37 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More